Study reports ETG prevents CMF chemotherapy induced hair loss.(Brief Article)

2002 JUL 16 - (NewsRx.com & NewsRx.net) -- Current Technology Corporation (CRTCF) announced Psycho-Oncology's publication, (2002;11:244-248) of the results of a pilot research study that examined whether ETG (electrotrichogenesis) could prevent or reduce hair loss in women with breast cancer undergoing CMF [cyclophosphamide, methotrexate, fluorouracil] chemotherapy

Twelve of the 13 female patients in this pilot study had good hair retention during chemotherapy and at the end of the study. The results also suggested that ETG treatment had a positive impact on quality of life. There were no reported side effects attributable to ETG. This study shows encouraging …